Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,034,267 | $108,625 | $252,526 | $347,107 |
| - Cash | $39,818 | $36,015 | $29,519 | $99,603 |
| + Debt | $3,645 | $4,644 | $4,961 | $5,628 |
| Enterprise Value | $1,998,094 | $77,254 | $227,968 | $253,132 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1,006 | -$536 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$79,550 | -$59,852 | -$32,293 | -$16,147 |
| % Margin | – | – | – | – |
| Net Income | -$80,556 | -$60,388 | -$31,167 | -$16,243 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.1 | -2.74 | -1.42 | -1.26 |
| % Growth | 23.4% | -93% | -12.7% | – |
| Operating Cash Flow | -$65,669 | -$42,641 | -$30,117 | -$13,982 |
| Capital Expenditures | -$2,768 | -$1,288 | -$2,166 | -$238 |
| Free Cash Flow | -$68,437 | -$43,929 | -$32,283 | -$14,220 |